Therefore, to investigate the potential oncogenic role of GLI3 in GC development, we employed CRISPR/Cas9 technology to generate GLI3 knockouts in 4 GC cell lines (HGC-27, GT38, SNU719, and SNU668) with 2 separate sgRNAs. This evidence concerns the gene GLI3 and gastric cancer.